Modulators of Rho-associated protein kinase

Inventors

Jones, Clifford D. • BUNYARD, PETER • Pitt, Gary • BYRNE, LIAM • Pesnot, Thomas • Guisot, Nicolas E. S.

Assignees

Redx Pharma Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11497751-B2

Patent

Publication Date

2022-11-15

Expiration Date


Abstract

This invention relates to novel compounds and pharmaceutical compositions comprising the same. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.

Core Innovation

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, including ROCK1/ROCK2 inhibitor compounds and ROCK pathway small-molecule examples. The compounds are defined by A1, A2 or A3 selected from CH, CR7 or N; B representing a 5 to 10 membered carbocyclic ring system or a 5 to 10 membered heterocyclic ring system; and R1 being L-R2, where L is a bond or -L1-L2-.

The linkage groups L1 and L2 are selected from enumerated bond, heteroatom-containing, and carbonyl-containing options, and the substituent framework further constrains R2, R4, R5, R6, R7, R8, R9, n, and ring-forming rules for RA, RB, RH, and RI. The disclosure includes structural scaffold subclasses and related structural representations, including indazole/triazole/benzotriazole-linked or phenoxy acetamide-type motifs, together with a broad but structured set of chemical entities within formula (I).

The provided content includes multiple synthesized examples and intermediates with analytical characterization by LC-MS or UPLC-MS and 1H NMR, including substituted heteroaromatic, triazole-indazole, benzamide, urea, quinoline, and boronate intermediates. Named examples and table entries are reported with structural depictions and salt forms in some cases, supporting the disclosed compound family.

Claims Coverage

The consolidated claim coverage includes compound claims for formula (I), pharmaceutical composition coverage in one item, and method claims for treating conditions by administering a therapeutic amount of a formula (I) compound. Across the items, the claims define one inventive chemical framework with multiple enumerated structural variables and one or more therapeutic-use frameworks directed to ROCK1 and/or ROCK2-modulated conditions and specified disease categories.

Formula (I) compound with pharmaceutically acceptable salts

A compound of formula (I) and pharmaceutically acceptable salts thereof, wherein A1, A2 or A3 are each independently selected from CH, CR7 or N; B is a 5 to 10 membered carbocyclic ring system or a 5 to 10 membered heterocyclic ring system; R1 is L-R2 with L being a bond or -L1-L2-; and L1 and L2 are selected from the listed bond, heteroatom-containing, and carbonyl-containing linkage options.

Enumerated substituent framework across R2 to R9

R2 is selected from broad enumerated groups including H, CN, alkyl, haloalkyl, substituted alkyl, cycloalkyl, heterocycloalkyl, and heteroaryl-containing groups; additional variables R4, R5, R6, R7, R8, and R9 are independently selected from their respective enumerated substituent sets; n is 0, 1, or 2; and ring-forming constraints for RA/RB and RH/RI are specified.

Therapeutic administration for ROCK1 and/or ROCK2-modulated conditions

A method of treating a condition which is modulated by ROCK1 and/or ROCK2 by administering to a patient in need thereof a therapeutic amount of a compound of formula (I) having the same defined selections for A1/A2/A3, B, R1 via L-L1-L2, and the enumerated substituent constraints.

Treatment of specified disease categories

A method of treating a condition selected from fibrotic diseases, auto-immune, inflammatory-fibrotic conditions, inflammatory conditions, central nervous system disorders, or cancer by administering to a patient in need thereof a therapeutic amount of a compound of formula (I).

Pharmaceutical composition with pharmaceutically acceptable excipient

A pharmaceutical composition comprising the compound of formula (I) and a pharmaceutically acceptable excipient.

The claims center on a structurally defined formula (I) compound class with enumerated ring, linker, and substituent options, together with therapeutic methods for ROCK1 and/or ROCK2-modulated conditions and specified disease categories, and one item also recites a pharmaceutical composition.

Stated Advantages

Improved selectivity.

Reduced cytotoxicity or greater solubility.

Favorable pharmacokinetics.

Favorable GRAS metabolite fragments.

Compounds have ROCK2 binding affinity categories including +++/++++.

Compounds exhibit ROCK2 IC50 less than 3 μM, optionally less than 0.3 μM.

Stated ROCK2 selectivity over ROCK1 is less than or equal to 5-fold.

Documented Applications

A method for treating a condition modulated by ROCK1 and/or ROCK2 by administering a therapeutic amount of a compound of formula (I).

Treatment of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSC), and interstitial lung disease (ILD).

Treatment of auto-immune, inflammatory-fibrotic, inflammatory, central nervous system disorders, and cancer.

Representative ROCK-pathway small-molecule examples are characterized by LC-MS or UPLC-MS and 1H NMR.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.